Distinct Roles of IL ‐4, IL ‐13, and IL ‐22 in Human Skin Barrier Dysfunction and Atopic Dermatitis
Top Cited Papers
Open Access
Abstract
Background: Atopic dermatitis (AD) is a chronic type‐2 inflammatory skin disease characterized by eczema and epithelial barrier dysfunction. Along with the type‐2 cytokines IL‐4 and IL‐13, IL‐22 contributes to AD pathogenesis. To date, most skin studies rely on reconstructed keratinocytes, which do not represent the real skin response. Objective: Here, we report the distinct effects of IL‐4, IL‐13, and IL‐22 on bio‐stabilized human skin with intact barriers and immune cells. Methods: Spatial transcriptomics on AD ‐lesions and non‐lesional skin was performed. Ex vivo skin barrier integrity was evaluated using electrical impedance spectroscopy ( EIS ), RNA ‐sequencing, and untargeted proteomics, complemented by analyses of skin biopsies from dupilumab‐treated AD patients. Results: Spatial transcriptomics demonstrated that AD lesions showed reduced expression of key barrier genes, including CLDN1, FLG, and FLG2. IL‐4, IL‐13, and IL‐22 disrupted the skin barrier in the ex vivo human skin. Combining type‐2 cytokines and IL‐22 alone downregulated genes critical for barrier function and keratinization. In addition, IL‐4 and IL‐13 downregulated antimicrobial peptides, while IL‐22 upregulated them. Interestingly, IL‐4 and IL‐13 reduced IL‐22Rα1, and IL‐22 upregulated IL‐4Rα, suggesting immune cross‐regulation. Proteomic analysis confirmed that all three cytokines (IL‐4, IL‐13, and IL‐22) reduced the expression of key skin barrier proteins, particularly filaggrin and claudin‐1. Dupilumab treatment of AD patients for 3 months restored IL‐4/IL‐13‐dysregulated genes, whereas it had limited effect on IL22‐associated pathways. Conclusion: This comprehensive study provides insights into the distinct immune profiles following IL‐4, IL‐13, and IL‐22 stimulation on human skin, highlighting their complex interplay in disrupting skin barrier function and modulating innate immune responses.Keywords
This publication has 52 references indexed in Scilit:
- Integrated analysis of multimodal single-cell dataCell, 2021
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialJournal of the American Academy of Dermatology, 2020
- The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signatureJournal of the American Academy of Dermatology, 2020
- Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabJournal of Allergy and Clinical Immunology, 2019
- Relations between epidermal barrier dysregulation and Staphylococcus species–dominated microbiome dysbiosis in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2018
- FOXO1 regulates VEGFA expression and promotes angiogenesis in healing woundsThe Journal of Pathology, 2018
- Calpain-14 and its association with eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2017
- Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skinJournal of Allergy and Clinical Immunology, 2016
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- TH17 and TH22 cells: A confusion of antimicrobial response with tissue inflammation versus protectionJournal of Allergy and Clinical Immunology, 2012